共 15 条
[1]
Carpenter C.C.J., Fischi M.A., Hammer S.M., Et al., Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel, JAMA, 176, pp. 146-154, (1996)
[2]
HIV infection: Consensus on how to treat gradually emerging with the publication of more guidelines, Drug Ther Perspect, 9, 11, pp. 8-11, (1997)
[3]
Hammer S.M., Squires K.E., Hughes M.D., Et al., A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, N Engl J Med, 337, pp. 725-733, (1997)
[4]
Hirsch M.S., Klibanski A., What price progress? Pseudo-Cushing's syndrome associated with antiretroviral therapy in patients with human immunodeficiency virus infection, Clin Infect Dis, 27, pp. 73-75, (1998)
[5]
Elwood W., Lipodystrophy: Cause for concern with protease inhibitor therapy?, Reactions, 713, pp. 3-4, (1998)
[6]
Striker R., Conlin D., Marx M., Et al., Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors, Clin Infect Dis, 27, pp. 218-220, (1998)
[7]
Miller K.K., Daly P.A., Sentochnik D., Et al., Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients, Clin Infect Dis, 27, pp. 68-72, (1998)
[8]
Roth V.R., Kravcik S., Angel J.B., Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors, Clin Infect Dis, 27, pp. 65-67, (1998)
[9]
De Luca A., Murri R., Damiano F., Et al., Buffalo hump in HIV-1 infection, Lancet, 352, (1998)
[10]
Labelling changes for anti-HIV drugs in Europe and the US, Reactions, 718, (1998)